Penwest Pharmaceuticals — Proxy Contest (June 2010)
43 slides from Penwest Pharmaceuticals's proxy contest presentation, Jun 14, 2010
Slide 1: Focused Business Plan and Execution: Driving Shareholder Value
Focused Business Plan and Execution: Driving Shareholder Value NASDAQ: PPCO June 2010
Slide 2: Forward-Looking Statements
Forward-Looking Statements The matters discussed herein contain forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, which may cause the actual results in future periods to be materially
Slide 3: Information Concerning Participants
Information Concerning Participants Information required to be disclosed with regard to the Company's directors, director nominees, officers and employees who, under the rules of the Securities and Exchange Commission (the "SEC"), are considered to be "participants" in the Company's solicitation of
Slide 4: Overview
Overview AaPenwest
Slide 5: Overview of Issues in Proxy Contest
Penwest at a critical point; needs steady experienced hand Now is not the time for change Current team has been successful implementing its plan Worked cooperatively with Tang and Edelman since their election and seriously considered their viewpoints Focused business plan is delivering performance -
Slide 6: Penwest Proxy Contest - What a Difference a Year Makes
Penwest Proxy Contest - What a Difference a Year Makes Last year's contest We presented our 2009 focused business plan Explained why we thought we could build shareholder value in short term and long term Wind down did not make sense We were proven right! Achieved our 2009 goals Stock appreciated 10
Slide 7: Execution of focused plan has created value for our shareholders
102% 138% Execution of focused Plan has created value for our shareholders 2009/2010 Stock Performance Dec 31, 2008 Dec 31, 2009 June 7, 2010 Date prior to Opana Settlement April 23, 2010 date prior to announcement of proxy contest 26% 26% June 8, 2010 Opana Patent Settlement
Slide 8: Business Plan and Execution
Business Plan and Execution
Slide 9: Highlights of Progress Over Past Year
Penwest - Highlights of Progress Over Past Year Posted 3 consecutive quarters of profitability, beginning with Q3 '09 Guided for full year profitability in 2010 Continued maximizing the value of Opana(r) ER with Endo Pharmaceuticals through: Ex-U.S. licensing collaboration Generic patent litigation
Slide 10: Company focused on key business areas
Company focused on 3 key business areas: Opana(r) ER- treatment for chronic, moderate-to-severe pain A0001 - being developed for Friedreich's Ataxia and MELAS Drug delivery technology - licensing and formulation work utilizing our proprietary TIMERx(r) extended release technology
Slide 11: Opana ER Overview
Developed using Penwest's TIMERx(r) technology Marketed by Endo Pharmaceuticals Indication: For the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time Opana(r) ER 2008 2009 Q1 2010 Endo's net sales $143 m $173m $49.8m
Slide 12: Opana ER TRx Demand Continuing Strong Growth Trend
Opana(r) ER TRx Demand Continuing Strong Growth Trend TRx Opana(r) ER Quarterly TRx Volume 1Q 10
Slide 13: Opana ER Patent Status
Opana(r) ER Patent Status Multiple generic filers in the U.S. Original filers: IMPAX, Actavis, Sandoz, Barr Recent filers: Watson, Roxanne (running 21/2 years behind) Original litigation settled 5, 10, 20, 40 mg IMPAX first to file IMPAX can launch January 1, 2013, others can launch after 180 days e
Slide 14: Opana ER Financials - U.S.
Penwest receives tiered royalty based on annual U.S. net sales of Opana(r) ER 22% up to $150m in sales 25%+ increasing in regular increments with net sales Top rate of 30% on sales Recorded $7.2m of royalty revenue for Q1 '10 Agreed to repay $28M in unfunded development costs through a temporary 50%
Slide 15: Opana ER Outside U.S.
Worldwide rights ex-U.S. jointly owned with Endo Economics to be shared 50/50 In June '09, announced deal with Valeant for Canada, Australia and New Zealand Seeking collaborations in Europe, South America and Asia Opana(r) ER Outside U.S.
Slide 16: A0001
A0001: ^ tocopherolquinone Coenzyme Q class of drugs, with improved bioavailability Marketed in the '70's in France for hypertension and myopathy Preclinical assays suggest strong potency and Phase I demonstrated good drug pharmacokinetics Targeting development in two mitochondrial disorders: Friedr
Slide 17: A0001: Friedreich's Ataxia
A0001: Friedreich's Ataxia Currently no approved therapies in U.S. or Europe Severe genetic disorder Degeneration of nerve and muscle tissue, loss of muscle control Impaired movements, muscle wasting Thickening of heart walls (cardiomyopathy) Caused by reduced level of fraxtaxin (key protein in mito
Slide 18: Phase IIa Friedreich's Ataxia Study
Phase IIa Friedreich's Ataxia Study 14 Days 28 Days High Dose Moderate Dose A0001 Placebo Control Single site- Children's Hospital of Philadelphia Double blind, randomized, placebo-controlled parallel group study Initiated trial in December 2009; expect to complete trial by end of Q3 '10 Endpoints:
Slide 19: A0001: MELAS Syndrome
A0001: MELAS Syndrome Currently no approved therapies in U.S. or Europe Rare, progressive, genetic neurodegenerative disorder Involves multiple system organs including CNS, skeletal, muscle, eye and cardiac muscle Presentation typically occurs with stroke-like symptom Onset typically 4-15 years of a
Slide 20: Phase IIa MELAS Study
Phase IIa "MELAS" Study 14 Days 28 Days High Dose A0001 Placebo Control Single site, Newcastle, UK Double blind, randomized, placebo-controlled parallel group study Initiated February '10. Expect to complete trial by end of Q3 '10 Endpoints: Primary - metabolic imaging, functional assessments, and a
Slide 21: A0001: Development To Date & Plan
A0001: Development To Date & Plan Completed Phase I safety program Completed 6-month preclinical tox program Established initial safety in animals and healthy volunteers Initiated Phase IIa trials in Friedreich's Ataxia and MELAS Expect to complete studies by end of Q3 '10 In parallel with developme
Slide 22: A0001: Why are we excited?
Significant unmet medical need; supports pricing Market exclusivity through orphan drug protection (U.S. 7 years, Europe 10 years) Receptive regulatory environment worldwide Well-organized medical communities through patient advocacy groups Established Initial Proof of Safety Seeking Proof of Biolog
Slide 23: Drug Delivery Technologies
Oral controlled release technology based on a natural gum matrix. Dual-delivery system which can release drugs or isomers at two different rates. Releases drug at the desired time and site in the GI tract. Releases drug in upper GI tract. Our oral controlled release technologies can be customized to
Slide 24: Drug Delivery Technology Licensing
Pursuing technology licensing collaborations with companies utilizing our extended release technologies and formulation expertise. Typical deal consists of: Signing fee Reimbursement of our development costs Revenue covers costs of R&D salaries and fixed overhead Success-based development milestones
Slide 25: Current Drug Delivery Collaborations
Current Drug Delivery Collaborations Signed 4 collaborations using TIMERx (r) for lifecycle management of marketed products Signed 2 deals in 2009 October 2009 - announced successful proof of principal in Phase I study of formulation under first Otsuka deal Several formulations currently in ongoing
Slide 26: 2010 Business Plan
Working closely with Endo to maximize the value of Opana(r) ER Completing both Phase IIa trials of A0001, analyzing the data and making a "go/no-go" decision Exploring potential licensing opportunities for A0001 in anticipation of the completion of the Phase IIa trials Growing our drug delivery busi
Slide 27: Cost Cutting Efforts and Financial Overview
Cost Cutting Efforts and Financial Overview
Slide 28: Details of Cost Cutting Effort
Details of Cost Cutting Effort Reduced headcount from 76 to 38 employees, or 50%, as we have focused the business plan Consolidated two office locations into one Narrowed the R&D portfolio to most promising opportunity in A0001 Drug delivery collaborations provide reimbursement of R&D salaries and f
Slide 29: Financially Solid - 2010 Guidance
Financially Solid - 2010 Guidance 2008 Actual 2009 Actual 2010 Guidance % Change Revenues $ 9m $ 24m $43-$45m 83% S,G &A $ 12m $ 9m $6.5-$7.5m (22)% R&D $ 21m $ 12m $10.5-$11.5m (8)% Net Loss $(27)m $ (1.5)m Profitable Weighted avg shares o/s 31.9m Improvement in revenues being driven by increased r
Slide 30: Balance Sheet - March 31, 2010
Balance Sheet - March 31, 2010 Cash $ 11.5m Line of Credit to be repaid by Sept 2010 $ 2.7m No capital required to execute business plan in 2010 Board announced intent to authorize a special cash dividend of $0.50 - $0.75/share in Q4 '10 following repayment of line of credit No capital required to e
Slide 31: Board Focus on Shareholder Value
Board Focus on Shareholder Value
Slide 32: Board Focus on Shareholder Value
Board Focus on Shareholder Value 2007 Focused effort to bring on new Board members; 50% of 2009 Board is new Jan. 2009 Announced focused business plan in response to challenging economic conditions and shareholder concerns Jan.-Dec. 2009 Significantly reduced headcount and expenses to support more f
Slide 33: This is Not an Entrenched Board
This is Not an Entrenched Board This is Not an Entrenched Board - -Directors added since 2005
Slide 34: Strong Balanced Working Board
Strong Balanced Working Board Directors have diverse skills including various functional expertise from the industry as well as representation of shareholders' perspective Board members are independent of each other Checks and balances exist Represents the perspectives of all shareholders Since Tang
Slide 35: 2010 Nominating & Governance Committee Conclusions
2010 Nominating & Governance Committee Conclusions
Slide 36: 2010 Nomination Process
2010 Nomination Process Tang and Edelman nominated 3 individuals for consideration Conducted thorough and fair review of each candidate Interviewed 2 of 3 candidates in person Offered compromise proposals - Tang and Edelman rejected N&G Committee: Anne VanLent, Chair David Meeker Peter Drake 3 direc
Slide 37: Comparison of Board Nominees
John Lemkey CFO at Tang Capital No operating experience Financial background - (skills represented on Board) No public company board experience Committee concerned about lack of independence from Tang Paul E. Freiman Current Chairman of the Board Veteran of the industry Former Chairman and CEO of Sy
Slide 38: Nominating & Governance Committee Recommendations
Nominating & Governance Committee Recommendations Committee recommended Board slate of Paul Freiman, Jennifer Good and Christophe Bianchi Recommendation based on: Concern regarding the independence of the Tang and Edelman slate Board nominees had more expertise and experience
Slide 39: Conclusions
Conclusions ZaPenwest
Slide 40: Disappointing to be here again a year later
Disappointing to be here again a year later We achieved our goals for 2009 - track record of execution Good momentum on deliverables in 2010 Stock price has risen significantly. Shareholders have been rewarded Executing on a plan that is similar to the plan they are now proposing Critical decisions/
Slide 41: Disruptive to the Company
Disruptive to the Company Proxy contest has been very costly for the Company and its shareholders Difficult on existing partnerships and negotiations of new collaborations Disruptive to morale of employees who are focused on executing against our plan
Slide 42: Tang and Edelman want Control!
Tang and Edelman want Control! Tang and Edelman nominees less qualified; less likely to represent the interests of all shareholders Tang and Edelman have no alternative plan Risk of disrupting execution of focused plan that is working -- proxy suggestion of management change and employee downsizing
Slide 43: AaFenwest
AaFenwest (Nasdaq: PPCO) June 2010 AaPenwest